Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the committee for medicinal products for human use (chmp)

  1. Peters, S.
  2. Dafni, U.
  3. Boyer, M.
  4. De Ruysscher, D.
  5. Faivre-Finn, C.
  6. Felip, E.
  7. Garrido, P.
  8. Girard, N.
  9. Guckenberger, M.
  10. Haanen, J.
  11. Le Pechoux, C.
  12. Mornex, F.
  13. Ozsahin, M.
  14. Paz-Ares, L.
  15. Planchard, D.
  16. Raben, D.
  17. Ramalingam, S.
  18. Reck, M.
  19. Smit, E.
  20. Stahel, R.
  21. Stenzinger, A.
  22. Swanton, C.
  23. Vallone, S.
  24. Garassino, M.C.
Revue:
Annals of Oncology

ISSN: 1569-8041,  0923-7534

Année de publication: 2019

Volumen: 30

Número: 2

Pages: 161-165

Type: Éditorial

DOI: 10.1093/ANNONC/MDY553 GOOGLE SCHOLAR lock_openAccès ouvert editor

Objectifs de Développement Durable

La source de données: Scopus